WT1肽疫苗用于儿童急性白血病异基因HSCT后维持免疫治疗:2期研究
这项2期临床研究评估了两种Wilms瘤1(WT1)肽疫苗MCI在儿童难治性急性白血病异基因造血干细胞移植后维持免疫治疗中的疗效与安全性。17例患者(中位年龄8.3岁)接受皮内注射,3年总生存(OS)率为70.6%(95%CI 43.1-86.6),高于30%的历史对照基准;12例临床缓解者3年OS率达91.7%,且其外周血WT1特异性细胞毒性T细胞频率在接种后显著升高。研究提示MCI对儿童难治性急性白血病有效且安全,可能通过预防复发改善生存。
要点
- 3年OS率为70.6%,高于30%历史对照基准。
- 12例临床缓解者3年OS率达91.7%。
- 免疫应答者3年OS率90.9%,显著高于免疫无应答者的40.0%。
核心结论
- MCI对儿童难治性急性白血病异基因HSCT后维持治疗显示有效且安全,可能通过预防复发改善生存。
研究设计与样本
- 2期临床研究,纳入17例儿童难治性急性白血病患者,中位年龄8.3岁(范围2-18岁),异基因HSCT后接受两种WT1肽疫苗MCI皮内注射。
主要发现
- 3年OS率(主要终点)为70.6%(95%CI 43.1-86.6),高于30%的历史对照基准。
- 12例临床缓解者(接种开始后1年持续完全缓解)3年OS率为91.7%(95%CI 53.9-98.7)。
- 12例临床缓解者外周血WT1特异性CTL频率接种后显著升高,第12周达峰值(接种前0.25%±0.08%,接种后1.07%±0.24%,P<.001)。
- 临床无应答者外周血WT1特异性CTL频率接种后无变化(接种前0.12%±0.2%,接种后0.20%±0.25%,P=.424)。
- 11例免疫应答者(较基线升高≥1.455倍)3年OS率为90.9%,显著高于5例免疫无应答者的40.0%(P=.027)。
关键数值与推荐
- 主要终点3年OS率为70.6%(95%CI 43.1-86.6),以30%为历史对照基准。
- 临床缓解者3年OS率91.7%(95%CI 53.9-98.7)。
- 免疫应答者3年OS率90.9%,免疫无应答者40.0%(P=.027)。
- WT1特异性CTL频率在临床缓解者接种后第12周达峰值(1.07%±0.24% vs 接种前0.25%±0.08%,P<.001)。
临床怎么用
- 异基因HSCT后接种WT1肽疫苗MCI可作为儿童难治性急性白血病的维持免疫治疗选择。
- 接种后外周血WT1特异性CTL频率升高及免疫应答可预测后续良好预后。
- 接种前外周血WT1特异性CTL频率升高提示患者可能获得有利预后。
局限性
- 无患者因MCI中止治疗,不良事件包括移植物抗宿主病均可管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 2 clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation maintenance cancer immunotherapy using 2 Wilms tumor 1 (WT1) peptide vaccines, MCI, for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years [range, 2-18]) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate (primary end point) was 70.6% (95% confidence interval [CI], 43.1-86.6); this rate was >30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders, who sustained complete remission at year 1 after the initiation of vaccination, had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7). WT1-specific cytotoxic T-cell (CTL) frequency in peripheral blood (PB) from all 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25% ± 0.08%; after, 1.07% ± 0.24%; P< .001), whereas WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12% ± 0.2%; after, 0.20% ± 0.25%; P = .424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ≥1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P = .027). Elevated WT1-specific CTL frequency in the PB before vaccination predicted the subsequent favorable patient prognosis. No patient discontinued treatment because of MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000005319.
引用
- Hashii Y, Oka Y, Sakata N, et al. WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study. Blood Adv. 2026. PMID: 42308229. doi:10.1182/bloodadvances.2025019352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。